GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » Intrinsic Value: Projected FCF

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Intrinsic Value: Projected FCF : $0.00 (As of Jun. 08, 2024)


View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-08), Pathfinder Cell Therapy's Intrinsic Value: Projected FCF is $0.00. The stock price of Pathfinder Cell Therapy is $0.0001. Therefore, Pathfinder Cell Therapy's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Pathfinder Cell Therapy's Intrinsic Value: Projected FCF or its related term are showing as below:

PFND's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.18
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Pathfinder Cell Therapy Intrinsic Value: Projected FCF Historical Data

The historical data trend for Pathfinder Cell Therapy's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy Intrinsic Value: Projected FCF Chart

Pathfinder Cell Therapy Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.07 -0.01 -0.01 -0.01 -0.01

Pathfinder Cell Therapy Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of Pathfinder Cell Therapy's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Pathfinder Cell Therapy's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pathfinder Cell Therapy's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's Price-to-Projected-FCF falls into.



Pathfinder Cell Therapy Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Pathfinder Cell Therapy's Free Cash Flow(6 year avg) = $-1.55.

Pathfinder Cell Therapy's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep15)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-1.5536+-6.73/0.8)/667.161
=-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pathfinder Cell Therapy  (OTCPK:PFND) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Pathfinder Cell Therapy's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0001/-0.034779188590896
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pathfinder Cell Therapy Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Traded in Other Exchanges
N/A
Address
12 Bow Street, Cambridge, MA, USA, 02138
Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Executives
John J Alam director 130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks director 100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines